РусскийNo products in the cart.
Lavomax, 125 mg 10 pcs
€21.84
Out of stock
Description
Low-molecular synthetic inducer of interferon that stimulates formation of all types of interferon in the body (alpha, beta, gamma and lambda).
The main producers of interferon in response to tiloron administration are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes.
After oral administration the maximum production of interferon is determined in the sequence intestine – liver – blood in 4-24 hours.
According to experimental data after single oral administration of Tiloron in dose equivalent to maximum daily dose for human the maximum concentration of interferon lambda in lung tissue is determined in 24 hours, of interferon alpha – in 48 hours.
Induction of interferon lambda in lung tissue increases antiviral protection of the respiratory tract during influenza and other respiratory viral infections.
In human leukocytes induces interferon synthesis. Stimulates bone marrow stem cells, depending on the dose increases antibody formation, reduces the degree of immunosuppression, restores the ratio of T-suppressors and T-helpers.
Effective against various viral infections including flu viruses, other acute respiratory viral infections, hepatitis viruses and herpesviruses.
The mechanism of antiviral action is connected to inhibition of translation of virus-specific proteins in infected cells.
Pharmacokinetics
After oral administration tiloron is quickly absorbed from the gastrointestinal tract. Bioavailability is 60%.
About 80% of tiloron is bound to plasma proteins. Thylorone is eliminated practically unchanged in intestine (70%) and kidney (9%).
Half-life period is 48 hours. Tiloron does not undergo biotransformation and does not accumulate in the body.
Indications
Indications
In adults, as part of the complex therapy of such diseases and conditions:
Active ingredient
Active ingredient
Composition
Composition
excipients:
magnesium hydroxycarbonate (magnesium carbonate heavy),
povidone K30,
calcium stearate;
coating:
sucrose, povidone K17, copovidone, magnesium hydroxycarbonate (magnesium carbonate light), titanium dioxide, colloidal silicon dioxide (aerosil A-380), quinoline yellow dye, sunset yellow dye, macrogol-6000, beeswax, liquid paraffin, talc.
How to take, the dosage
How to take, the dosage
Ingestion, after meals.
For treatment of viral hepatitis A – 0.125 g 2 times on the first day, then – 0.125 g every other day. The course dose is 1.25 g (10 tablets).
To treat acute hepatitis B: first and second day – 0.125 g, then 0.125 g every other day; course dose – 2 g (16 tablets). In prolonged course of hepatitis B – 0.125 g 2 times a day during the first day, then – 0.125 g every other day. Course dose – 2.5 g (20 tablets)
In chronic hepatitis B in initial phase of treatment (2.5 g – 20 tablets): during the first 2 days – 0.25 g, then – 0.125 g once a day. The continuation phase is from 1.25 g (10 pills) to 2.5 g (20 pills) – 0.125 g per week.
The course dose of Lavomax® is 3.75-5 g (from 30 to 40 tablets of 0.125 g); therapy duration – 3.5-6 months, depending on the results of biochemical, immunological, morphological tests which show the degree of the process activity.
In case of acute hepatitis C: in the first and second days – 0.125 g, then – 0.125 g every other day. Course dose – 2,5 g (20 tablets)
In chronic hepatitis C, in the initial phase of treatment (2,5 g – 20 tablets): in the first two days – 0,25 g, then – 0,125 g every other day.
The continuation phase (2.5 g – 20 tablets) is 0.125 g per week. The course dose of Lavomax® is 5 g (40 tablets of 0.125 g); therapy duration – 6 months, depending on results of biochemical, immunological, morphological markers of the process activity.
In the treatment of influenza and other acute respiratory viral infections: during the first two days of the disease – 0.125 g, then – 0.125 g a day. The course dose is 0.75 g (6 tablets of 0.125 g).
For the prevention of flu and other acute respiratory viral infections: 0.125 g once a week for 6 weeks. For a course of 6 tablets of 0.125 g.
For the treatment of herpetic, CMV-infection: in the first two days 0.125 g and then 0.125 g a day. The course dose is 2.5 g (20 tablets of 0.125 g).
In case of urogenital and respiratory chlamydia, nongonococcal urethritis: 0.125 g during the first two days, then 0.125 g every other day. The course dose is 1.25 g (10 tablets of 0.125 g).
In combination therapy of pulmonary tuberculosis: during the first two days 0.25 g and then 0.125 g every other day. The course dose is 2.5 g (20 tablets of 0.125 g).
In combination therapy of infectious-allergic and viral encephalomyelitis the dose is stated individually; the course of treatment is 4 weeks.
Interaction
Interaction
Compatible with antibiotics and agents of traditional treatment of viral and bacterial diseases.
The drug Lavomax® has no clinically significant interaction with antibiotics, agents of traditional treatment of viral and bacterial diseases and alcohol.
Special Instructions
Special Instructions
Impact on driving and operating machinery
The use of the drug does not affect the ability to drive vehicles and engage in other potentially dangerous activities requiring increased concentration and quick psychomotor reactions.
Contraindications
Contraindications
Side effects
Side effects
Overdose
Overdose
Similarities
Similarities
Additional information
| Weight | 0.015 kg |
|---|---|
| Shelf life | 2 years |
| Conditions of storage | In a dry, light-protected place at a temperature not exceeding 25 °C |
| Manufacturer | Nizhpharm AO, Russia |
| Medication form | pills |
| Brand | Nizhpharm AO |
Related products
€34.27
Immune system
€21.27
Immune system
€22.76
Immune system
€29.34
Immune system
€24.63
Immune system
€31.82
Immune system
€29.90
Immune system
€31.37
Buy Lavomax, 125 mg 10 pcs with delivery to USA, UK, Europe and over 120 other countries.
